

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A process of reducing cerebrospinal fluid flow obstruction comprising:

administering a therapeutic dose of a defibrinogenic clot-reducing agent of a natural or synthetic reptile peptide to a subject having ~~preconditions~~ a precondition to obstructive hydrocephalus symptoms or obstructive hydrocephalus symptoms; and

~~maintaining a therapeutic amount of~~ the defibrinogenic clot-reducing agent within cerebrospinal fluid of the subject ~~for a period of time sufficient~~ to reduce cerebrospinal fluid flow obstruction.

2. (Original) The process of claim 1 wherein the administering is by catheter.

3. (Currently amended) The process of claim 1 wherein the administering is by a device selected from the group consisting of: intrathecal catheter[[.]] and intraventricular catheter ~~and an injection~~.

4-8 (Canceled)

9. (Currently amended) The process of claim [[4]] 1 wherein the defibrinogenic clot-reducing agent is ~~a natural or synthetic reptile peptide, a combination thereof, a functional fragment thereof of said natural or synthetic reptile peptide,~~ a pharmacologically acceptable salt of said natural or synthetic reptile peptide, ester of said natural or synthetic reptile peptide, amide

of said natural or synthetic reptile peptide, or prodrug thereof of said natural or synthetic reptile peptide.

10-11 (Canceled)

12. (Currently amended) The process of claim ~~[[4]]~~ 1 wherein the defibrinogenic clot-reducing agent is ancrod, a functional fragment ~~thereof of ancrod~~, a pharmacologically acceptable salt of ancrod, ester of ancrod, amide of ancrod, or prodrug ~~thereof of ancrod~~.

13-23 (Canceled)

24. (Currently amended) A process of reducing cerebrospinal fluid flow obstruction comprising:

administering ~~a therapeutic dose of a~~ defibrinogenic clot-reducing agent comprising ancrod to a subject having obstructive hydrocephalus; and

~~maintaining a therapeutic amount of the~~ clot-reducing agent comprising ancrod within the subject ~~for a period of time sufficient~~ to reduce cerebrospinal fluid flow obstruction.

25-38 (Canceled)